ClinicalTrials.gg
CompletedNCT05565560Updated Oct 1, 2026

A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Apremilast in Plaque Psoriasis, sponsored by Amgen. Completed at 29 sites in Japan. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Updated Oct 1, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
37th of 44
21 · median 103
Started
2023
with 3 others
Phase 3
18 of 44
none open now
Registered
36th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 37th largest by enrollment, is one of 4 that started in 2023, is one of 18 in phase 3, and was the 36th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of apremilast in children and adolescents (ages 6 through 17 years) with moderate to severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Plaque Psoriasis
  • Apremilast
  • AMG 407
  • Moderate to Severe Plaque Psoriasis
  • Pediatric Plaque Psoriasis
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese participants aged 6 to 17 years at screening
  • Participants must have a weight of ≥ 15 kg
  • Diagnosis of chronic plaque psoriasis for at least 3 months prior to screening
  • Has moderate to severe plaque psoriasis at screening and baseline as defined by:
  • PASI score ≥ 12; and
  • BSA ≥ 10; and
  • sPGA ≥ 3 (moderate to severe)
  • Disease inadequately controlled by or for ≥ 1 topical therapy for psoriasis
  • Candidate for systemic therapy or phototherapy

Exclusion criteria

Exclusion Criteria:

  • Psoriasis flare or rebound within 4 weeks prior to screening
  • Evidence of skin conditions, other than psoriasis, that would interfere with clinical assessments
  • Other than psoriasis, history of any (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease
  • Prior history of suicide attempt at any time in the participant's lifetime prior to screening or baseline in the study, or major psychiatric illness requiring hospitalization within 3 years prior to signing the assent and
  • Guttate, erythrodermic, or pustular psoriasis at screening and baseline
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Apremilast

    Participants with a weight between ≥ 15 kg to \< 50 kg will receive apremilast 20 mg twice daily (BID) tablet. Participants weighing ≥ 50 kg will receive apremilast 30 mg BID tablet.

    Drug: Apremilast

Interventions

  • Oral tablets

    Also known as: AMG 407, Otezla

06

What researchers measure

Primary outcomes

  1. Achievement of a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least 2 points reduction from baseline at Week 16

    Time frame: Week 16

Secondary outcomes

  1. Achievement of at least 75% reduction in Psoriasis Area and Severity Index (PASI) score (PASI-75) from baseline at Week 16

    Time frame: Baseline, Week 16

  2. Achievement of at least a 50% reduction in PASI score (PASI-50) from baseline at Week 16

    Time frame: Baseline, Week 16

  3. Percent change from baseline in total PASI score at Week 16

    Time frame: Baseline, Week 16

  4. Percent change from baseline in affected body surface area (BSA) at Week 16

    Time frame: Baseline, Week 16

  5. Achievement of Children Dermatology Life Quality Index (CDLQI) (0/1) at Week 16

    Time frame: Week 16

  6. Change from baseline in CDLQI score at Week 16

    Time frame: Baseline, Week 16

  7. Number of participants with treatment-emergent adverse events

    Time frame: Approximately 52 weeks

  8. Number of participants with clinically significant changes in vital signs

    Time frame: Approximately 62 weeks

  9. Number of participants with clinically significant changes in laboratory abnormalities

    Time frame: Approximately 62 weeks

07

Study locations

29 sites
  • Nagoya City University Hospital
    Nagoya, Aichi-ken 467-8602, Japan
  • Fukuoka University Hospital
    Fukuoka, Fukuoka 814-0180, Japan
  • Hospital of the University of Occupational and Environmental Health, Japan
    Kitakyushu-shi, Fukuoka 807-8556, Japan
  • Kurume University Hospital
    Kurume-shi, Fukuoka 830-0011, Japan
  • Fukushima Medical University Hospital
    Fukushima, Fukushima 960-1295, Japan
  • Gifu University Hospital
    Gifu, Gifu 501-1194, Japan
  • Gunma University Hospital
    Maebashi, Gunma 371-8511, Japan
  • Takagi Dermatological Clinic
    Obihiro-shi, Hokkaido 080-0013, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Kanazawa Medical University Hospital
    Kahoku-gun, Ishikawa-ken 920-0293, Japan
  • Takeoka Dermatology Clinic
    Marugame-shi, Kagawa-ken 763-0074, Japan
  • Takamatsu Red Cross Hospital
    Takamatsu, Kagawa-ken 760-0017, Japan
  • Saruwatari Dermatology Clinic
    Kagoshima, Kagoshima-ken 890-0046, Japan
  • Tokai University Hospital
    Isehara-shi, Kanagawa 259-1193, Japan
  • St Marianna University Hospital
    Kawasaki-shi, Kanagawa 216-8511, Japan
  • University Hospital Kyoto Prefectural University of Medicine
    Kyoto, Kyoto 602-8566, Japan
  • Shinshu University Hospital
    Matsumoto-shi, Nagano 390-8621, Japan
  • Nagasaki University Hospital
    Nagasaki, Nagasaki 852-8501, Japan
  • University of the Ryukyus Hospital
    Ginowan-shi, Okinawa 901-2725, Japan
  • Kansai Medical University Hospital
    Hirakata-shi, Osaka 573-1191, Japan
  • Nippon Life Hospital
    Osaka, Osaka 550-0006, Japan
  • Kindai University Hospital
    Osakasayama-shi, Osaka 589-8511, Japan
  • Dokkyo Medical University Hospital
    Shimotsuga-gun, Tochigi 321-0293, Japan
  • Sugai Dermatology Park Side Clinic
    Utsunomiya, Tochigi 321-0954, Japan
  • St Lukes International Hospital
    Chuo-ku, Tokyo 104-8560, Japan
  • Teikyo University Hospital
    Itabashi-ku, Tokyo 173-8606, Japan
  • Mita Dermatology Clinic
    Minato-ku, Tokyo 108-0014, Japan
  • Seibo International Catholic Hospital
    Shinjuku-ku, Tokyo 161-8521, Japan
  • Tokyo Medical University Hospital
    Shinjyuku-ku, 160-0023, Japan
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Nov 2025, 33 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 33 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2022
First posted
Oct 4, 2022
StartActual
Jan 25, 2023
Primary completionActual
Nov 20, 2025
CompletionActual
Sep 3, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 1, 2026
Enrollment
17→21
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Active, not recruiting→Completed
    Enrollment 17→21
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05565560
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Jan 25, 2023
Primary completion
Nov 20, 2025
Completion
Sep 3, 2026
Last update
Oct 1, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion